U.S. markets open in 1 hour 36 minutes
  • S&P Futures

    3,722.50
    +52.50 (+1.43%)
     
  • Dow Futures

    29,681.00
    +338.00 (+1.15%)
     
  • Nasdaq Futures

    11,506.50
    +190.25 (+1.68%)
     
  • Russell 2000 Futures

    1,690.30
    +27.80 (+1.67%)
     
  • Crude Oil

    77.89
    +1.18 (+1.54%)
     
  • Gold

    1,648.30
    +14.90 (+0.91%)
     
  • Silver

    18.74
    +0.26 (+1.38%)
     
  • EUR/USD

    0.9645
    +0.0033 (+0.35%)
     
  • 10-Yr Bond

    3.8780
    0.0000 (0.00%)
     
  • Vix

    30.98
    +1.06 (+3.54%)
     
  • GBP/USD

    1.0808
    +0.0125 (+1.17%)
     
  • USD/JPY

    144.3430
    -0.3370 (-0.23%)
     
  • BTC-USD

    20,288.04
    +1,408.71 (+7.46%)
     
  • CMC Crypto 200

    463.75
    +30.65 (+7.08%)
     
  • FTSE 100

    7,028.69
    +7.74 (+0.11%)
     
  • Nikkei 225

    26,571.87
    +140.32 (+0.53%)
     

Lifshitz Law Firm, P.C. Announces Investigations of 3D Systems Corp. (NYSE: DDD), Acadia Pharmaceuticals, Inc. (NasdaqGS: ACAD), ChemoCentryx, Inc. (NasdaqGS: CCXI), and Peloton Interactive, Inc (NasdaqGS: PTON)

·4 min read

NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) --

3D Systems Corp. (NYSE: DDD)

Lifshitz Law Firm, P.C. announces that a class action complaint was filed against DDD alleging that DDD made false and/or misleading statements and/or failed to disclose that: (1) DDD lacked proper internal controls over financial reporting; and (2) as a result, DDD’s public statements were materially false and/or misleading at all relevant times.

If you are a DDD investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Acadia Pharmaceuticals, Inc. (NasdaqGS: ACAD)

Lifshitz Law Firm, P.C. announces that a class action complaint was filed against ACAD alleging that ACAD made false and/or misleading statements and/or failed to disclose that: (1) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (2) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (3) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you are a ACAD investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

ChemoCentryx, Inc. (NasdaqGS: CCXI)

Lifshitz Law Firm, P.C. announces that a class action complaint was filed against CCXI alleging that CCXI misrepresented and/or failed to disclose to investors that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx’s NDA for avacopan for the treatment of ANCA associated vasculitis; and (4) as a result of the foregoing, CCXI’s public statements were materially false and misleading at all relevant times.

If you are a CCXI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

Peloton Interactive, Inc (NasdaqGS: PTON)

Lifshitz Law Firm, P.C. announces that a class action complaint was filed against PTON alleging that PTON made false and/or misleading statements and/or failed to disclose that: (1) in addition to the tragic death of a child, PTON's Tread+ had caused a serious safety threat to children and pets as there were multiple incidents of injury to both; (2) safety was not a priority to PTON as PTON were aware of serious injuries and death resulting from the Tread+ yet did not recall or suggest a halt of the use of the Tread+; (3) as a result of the safety concerns, the U.S. Consumer Product Safety Commission ("CPSC") declared the Tread+ posed a serious risk to public health and safety resulting in its urgent recommendation for consumers with small children to cease using the Tread+; (4) the CPSC also found a safety threat to Tread+ users if they lost balance; and (5) PTON’s statements about PTON’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you are a PTON investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com.

ATTORNEY ADVERTISING.© 2021 Lifshitz Law Firm, P.C. The law firm responsible for this advertisement is Lifshitz Law Firm, P.C., 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz Law Firm, P.C.
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: jml@jlclasslaw.com